The latest announcement is out from Nurix Therapeutics ( (NRIX) ).
Nurix Therapeutics, a clinical-stage biopharmaceutical company, has appointed Anil Kapur to its board of directors. With over 25 years of experience in drug commercialization, including successful launches like Imbruvica and Darzalex, Kapur is expected to bring valuable strategic insights as Nurix moves forward with its drug pipeline, particularly NX-5948, poised for pivotal trials in 2025. This addition is seen as a significant step in advancing Nurix’s targeted protein modulation therapies aimed at treating cancer and inflammatory diseases.
See more insights into NRIX stock on TipRanks’ Stock Analysis page.
